Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
BAUSCH + LOMB AND NICOX ANNOUNCE FDA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%

November 2, 2017

View Press Release Corporate presentation Contact us
Previous